ESTRO 2023 - Abstract Book

S1299

Digital Posters

ESTRO 2023

Purpose or Objective Chemotherapy-induced alopecia is one of the most common side effects of chemotherapy. Many patients ask about this topic, but the received answers are not always satiating. Other patients refuse categorically the treatment in order to escape this unavoidable side effect.The aimof the study is to describe the clinical characteristics of hair loss and regrowth in cancer patients undergoing chemotherapy with the intention to increase the awareness about this topic within the oncology healthcare professionals and improve the patient education. Materials and Methods This is a single-center descriptive cohort study. The data was carried out from the interrogation and the clinical examination of the patients with cancer undergoing chemotherapy. Results Seventy-one adult patients were included in the study. The average age was 61[24-80 y.o] with a female predominance (72%). The most represented cancer was breast cancer (54%) then lung cancer (17%) and gynaecological cancers (11.3%). The patients had received an average of 5 courses of chemotherapy with different protocols; the most frequent ones were based on Epirubicin-Cyclophosphamide and Docetaxel (25.4%), Paclitaxel-Carboplatin (18.3%) and Epirubicin Cyclophosphamide alone (18.3%). The majority of the protocols were based on bi-chemotherapy (83%) and considered very alopeciant (90%). Patients'hair before chemotherapy was considered of good quality in 82% and harsh and brittle in the rest of patients. Hair color before chemotherapy was described as dark in 49.3%, mixed “white and black” in 43.7% and light or white in the rest of patients. Hair loss was progressive in 71.8% and partial in 56.3%. Hair regrowth was found in (38/71). The average time interval for regrowth from the start of chemotherapy was 120 days. Hair quality during regrowth was different in (12/38); with mentionned better quality in (6/38) and worse quality in (6/38). Hair color during regrowth was different in (11/38); white in (9/38) and another lighter color in (2/38). Cutaneo-phanerial disorders were associated with hair loss in 43.7% affecting the skin in 22 patients, the nails in 21 patients and the eyelashes and eyebrows in 7 patients. Conclusion Hair loss appears to be a multi-dimensional cutaneous-phanerial process. Understanding this process is essential for all the oncology healthcare professionals in order to properly educate patients. In the contrast to the literature, our study showed that hair regrowth seems to start during chemotherapy. Faced with the current unavailability of effective and accessible means of prevention, the regrowth during chemotherapy as well as the significant percentage of hair regrowth with better quality could constitute a ray of hope to share with the patient before his chemotherapy in order to encourage him to better adhere to the treatment. 1 University Medical Center Mainz, Department of Radiation Oncology , Mainz, Germany; 2 German Cancer Research Center (dkfz), German Cancer Consortium (DKTK) Partner Site Mainz, Heidelberg , Germany; 3 University Medical Center Mainz, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), Mainz, Germany; 4 German Cancer Research Center (dkfz), German Cancer Consortium (DKTK) Partner Site Mainz, Heidelberg, Germany; 5 University of Freiburg – Medical Center, Department of Radiation Oncology , Freiburg, Germany; 6 German Cancer Research Center (dkfz), German Cancer Consortium (DKTK) Partner Site Freiburg, Heidelberg, Germany; 7 University Hospital Schleswig-Holstein, Department of Radiation Oncology, Kiel, Germany; 8 University of Leipzig Medical Center, Department of Radiation Oncology , Leipzig , Germany; 9 University Medical Center Mainz , Department of Radiation Oncology , Mainz, Germany Purpose or Objective For personalized therapy of patients with bone metastases, the remaining lifetime should be estimated using scoring tools if possible. The aim of this analysis was to develop a new tool specifically designed for elderly patients with spinal bone metastases (SBM) to estimate their 12- and 24-month survival rates. Materials and Methods This retrospective analysis included 212 elderly patients with SBM (median age 76 years, range 65-90 years) treated with palliative radiotherapy (RT) in the period 2015 to 2020 at the University Medical Center Mainz. The most common underlying primaries were prostate (n=60, 28%), breast (n=36, 17%), and lung (n=43, 20%) carcinomas. Multiple patient-, tumor-, and treatment-specific factors were documented, and their prognostic relevance for predicting residual survival after palliative RT was statistically analyzed. Factors achieving significance (p < 0.05) on multivariate analysis were used for score development. Results In multivariate analysis, the following 3 factors were associated with significant improvement in survival after palliative RT for spinal bone metastases: The majority of patients were metastatic (43.3%) with a history of cerebral radiotherapy in 3 patients. The onset of hair loss after chemotherapy was noticed by patients after an average time of 16 days. PO-1600 Survival prognosis of elderly patients irradiated for spinal bone metastases with a new scoring tool T. Bostel 1,2 , D. Wollschläger 3 , J. Geis 1,4 , E. Nikolaidou 1,4 , A. Fabian 5,6,7 , N.H. Nicolay 5,6,8 , H. Schmidberger 9,2